General molecular and cellular mechanisms for renal and cardiac remodeling in chronic kidney disease: a target for nephrocardioprotection

Kozlovskaia L.V.; Bobkova I.N.; Nanchikeeva M.L.; Chebotareva N.V.; Li O.A.; Plieva O.K.

doi:https://doi.org/

Kozlovskaia L.V.

Pervyĭ Moskovskiĭ gosudarstvennyĭ meditsinskiĭ universitet im. I.M. Sechenova

Bobkova I.N.

Otdel nefrologii NII uronefrologii i reproduktivnogo zdorov'ia cheloveka Pervogo MGMU im. I.M. Sechenova Minzdrava Rossii

SPIN RSCI: 4217-4514

Nanchikeeva M.L.

Oblastnaia klinicheskaia bol'nitsa, Vladimir

Chebotareva N.V.

Medical University «Russian University of Friendship of Peoples» Ministry of Health of the Russian Federation, Moscow, Russia, 117198

Li O.A.

Otdel nefrologii NII uronefrologii i reproduktivnogo zdorov'ia cheloveka Pervogo MGMU im. I.M. Sechenova Minzdrava Rossii

Plieva O.K.

Kafedra nefrologii i gemodializa FPPOV Pervogo MGMU im. I.M. Sechenova Minzdrava Rossii

General molecular and cellular mechanisms for renal and cardiac remodeling in chronic kidney disease: a target for nephrocardioprotection

Authors:

Kozlovskaia L.V., Bobkova I.N., Nanchikeeva M.L., Chebotareva N.V., Li O.A., Plieva O.K.

More about the authors

Journal: Therapeutic Archive. 2013;85(6): 66‑72

Read: 1687 times

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Kozlovskaia LV, Bobkova IN, Nanchikeeva ML, Chebotareva NV, Li OA, Plieva OK. General molecular and cellular mechanisms for renal and cardiac remodeling in chronic kidney disease: a target for nephrocardioprotection. Therapeutic Archive. 2013;85(6):66‑72. (In Russ.)

Использование инфографики авторами научных работ

Close metadata

Recommended articles:

The effect of ethylmethylhydroxypyridine succinate on the parameters of chronic neuroinflammation and plastic processes in the brain of old rats during course of dexamethasone administration. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(9):115-121

Localization features of FAP-positive activated stromal cells in fibrosis in patients with new coronavirus infection COVID-19. Russian Journal of Archive of Pathology. 2024;(6):5-14

Abstract:

The lecture considers a number of molecular and cellular mechanisms underlying the structural and functional rearrangement and development of renal and cardiac fibrosis in chronic kidney disease (CKD). It details the key component of disadaptative organ remodeling (the formation of myofibroblasts via epithelial-mesenchymal and endothelial-mesenchymal transdifferentiation) and the role of leading angiofibrogenic mediators (angiotensin II, transforming growth factor-Β type 1, a plasminogen activator inhibitor type 1, etc.) in the regulation of these processes. Investigation of the molecular and cellular bases of organ fibrosis, including the factors of dysregulated activation, differentiation and survival of microfibroblasts, makes it possible to specify the mechanisms of action of traditional nephro- and cardioprotective agents, to offer a possibility for a goal-oriented (target) effect on individual fibrogenic components, and to expand the arsenal of medications suppressing renal and cardiac remodeling.

Keywords:

cardiac fibrosis

nephrofibrosis

epithelial-mesenchymal transdifferentiation

endothelial-mesenchymal transdifferentiation

myofibroblasts

angiotensin II

plasminogen activator inhibitor

transforming growth factor-Β1

vascular endothelial growth factor

cardio- and nephroprotection

Authors:

Kozlovskaia L.V.

Pervyĭ Moskovskiĭ gosudarstvennyĭ meditsinskiĭ universitet im. I.M. Sechenova

Bobkova I.N.

Otdel nefrologii NII uronefrologii i reproduktivnogo zdorov'ia cheloveka Pervogo MGMU im. I.M. Sechenova Minzdrava Rossii

SPIN RSCI: 4217-4514

Nanchikeeva M.L.

Oblastnaia klinicheskaia bol'nitsa, Vladimir

Chebotareva N.V.

Medical University «Russian University of Friendship of Peoples» Ministry of Health of the Russian Federation, Moscow, Russia, 117198

Li O.A.

Otdel nefrologii NII uronefrologii i reproduktivnogo zdorov'ia cheloveka Pervogo MGMU im. I.M. Sechenova Minzdrava Rossii

Plieva O.K.

Kafedra nefrologii i gemodializa FPPOV Pervogo MGMU im. I.M. Sechenova Minzdrava Rossii

Close metadata

References:

Kalluri R., Neilson E.G. Epithelial-mesenchymal transitition and its implication for fibrosis. J Clin Invest 2003; 112 (12): 1776-1784.
Yoshimatsu Y., Watabe T. Role of TGF-Β1 signals in endothelial-mesenchymal transitition in cardiac fibrosis. Intern J Inflam 2011;2011:724080. doi: 10.4061/2011/724080. Epub 2011 Nov 30.
Zeisberg M., Neilson E.G. Biomarkers for epithelial-to-mesenchymal transitition. J Clin Invest 2009; 119 (6): 1429-1437.
Leask A. Potential therapeutic targets for cardiac fibrosis: TGF-Β, angiotensin, endothelin, CCN2 and PDGF? Partners of fibroblast activation. Circul Res 2010; 106 (11): 1675-1680.
Liu Y. Epithelial to mesenchymal transition in renal fibrogenesis: pathologic significance, molecular mechanism, and therapeutic intervention. J Am Soc Nephrol 2004; 15: 1-12.
Eddy A.A., Fogo A.V. Plasminogen activator inhibitor-1in chronic kidney disease: evidence and mechanisms of action. J Am Soc Nephrol 2006; 17: 2999-3012.
Takeda N., Manabe I. Cellular interplay between cardiomyocytes and nonmyocytes in cardiac remodeling. Intern J Inflam 2011; 2011: 535241. doi: 10.4061/2011/535241. Epub 2011 Sep 18.
Porter K.E., Turner N.A. Cardiac fibroblasts: at the heart of myocardial remodeling. Pharmacol Ther 2009; 123: 255-278.
Zeisberg E.M., Tarnavski O., Zeisberg M. et al. Endothelial-to-mesenchymal transitition contributes to cardiac fibrosis. Nature Med 2007; 13 (8): 952-961.
Liu Y. New insights into epithelial-mesenchymal transitition contribute in kidney fibrosis. J Am Soc Nephrol 2010; 21: 212-222.
Zeisberg E.M., Kalluri R. Epithelial-to-mesenchymal transitition contributes in renal fibrosis. J Molecul Med 2004; 82 (3): 175-181.
Kriz W., Greitz N., Lemley K.V. Progression of glomerular diseases: is the podocyte the culprit? Kidney Int 1998; 54: 687-697.
Lemley K.V., Lafayette A., Safai G. et al. Podocytopenia and disease severity in IgA nephropathy. Kidney Int 2002; 61: 1475-1485.
Galichon P., Hertig A. Epithelial to mesenchymal transitition a biomarker in renal fibrosis: are we ready for bedside? Fibrogenes Tissue Repair 2011; 4: 11-17.
Kriz W., Kaissling B., Le Hir M. Epithelial-mesenchymal transitition in kidney fibrosis: fact or fantasy? J Clin Invest 2011; 121: 468-472.
Mukhin N.A., Kozlovskaya L.V., Bobkova I.N. i dr. Indutsiruemye proteinuriei mekhanizmy remodelirovaniya tubulointerstitsiya i vozmozhnosti nefroprotektsii pri glomerulonefrite. Vestn RAMN 2005; 1: 3-8.
Kozlovskaya L.V., Bobkova I.N., Plieva O.K. i dr. Znachenie issledovaniya v moche molekulyarnykh mediatorov immunnogo vospaleniya i fibroza v pochke pri khronicheskom glomerulonefrite. Ter arkh 2004; 9: 84-87.
Nanchikeeva M.L., Konechnaya E.Ya., Bulanov M.N. i dr. Vozmozhnosti rannei diagnostiki porazheniya pochek u bol'nykh gipertonicheskoi bolezn'yu. Ter arkh 2004; 9: 29-34.
Bobkova I.N., Chebotareva N.V., Kozlovskaya L.V. i dr. Ekskretsiya s mochoi monotsitarnogo khemotaksicheskogo proteina-1 i transformiruyushchego faktora rosta Β1 kak pokazatel' progressirovaniya khronicheskogo glomerulonefrita. Ter arkh 2006; 5: 9-14.
Schrijvers B.F., Flyvbjerg A., De Vriese A.S. The role of vascular endothelial growth factor (VEGF) in renal pathophysiology. Kidney Int 2004; 65 (6): 2003-2017.
Fogo A.B., Kon V. The glomerulus - a view from the inside-the endothelial cell. Int J Biochem Cell Biol 2010; 42 (9): 1388-1397.
Li O.A., Bobkova I.N., Kozlovskaya L.V. Klinicheskoe znachenie opredeleniya matriksnykh metalloproteinaz i ikh ingibitorov v moche bol'nykh khronicheskim glomerulonefritom. Ter arkh 2009; 8: 10-14.
Li O., Bobkova I., Kozlovskaya L., Varshavskiy V. Matrix metalloproteinases (MMP) and its inhibitors in chronic glomerulonephritis (CGN): association with clinical activity and proteinuric remodeling of renal tubulointerstitium. Nephrol Dial Transplant Plus 2010; 1 (3): 375.
Cheng S., Lovett D.H. Gelatinase A (MMP-2) is necessary and sufficient for renal tubular cell epithelial-mesenchymal transformation. Am J Pathol 2003; 162: 1937-1949.
Fogo A.B. The role of angiotensin II and plasminogen activator inhibitor-1 in progressive glomerulosclerosis. Am J Kidney Dis 2000; 35: 179-188.
Ruiz-Ortega M., Ruperez M., Esteban V. et al. Angiotensin II: a key factor in the inflammatory and fibrotic response in kidney disease. Nephrol Dial Transplant 2006; 21: 16-20.